You haven't searched anything yet.
COMPANY SUMMARY:
At Intercept, our mission is to build a healthier tomorrow for patients with progressive non-viral liver diseases. Intercept’s lead product, obeticholic acid (OCA), is a first-in-class farnesoid X receptor (FXR) agonist marketed under the brand name "Ocaliva®" in the U.S., EU and Canada for the treatment of patients with primary biliary cholangitis (PBC), a rare autoimmune liver disease. In 2016, Ocaliva® was the first medication to be approved for PBC in over twenty years, and sales continue to grow.
Intercept has also established the leading clinical development program in advanced fibrosis due to nonalcoholic steatohepatitis (NASH), a disease that impacts the lives of millions of people in the U.S. alone and for which there are currently no available treatments. The 18 month interim analysis of the REGENERATE study of OCA remains the only readout from a Phase 3 trial to have shown positive results in the disease. A second Phase 3 trial, REVERSE, is evaluating OCA in patients with compensated cirrhosis due to NASH with topline results expected in 2022.
People at Intercept are passionate about patients. You’ll see their photos lining our walls and hear their stories in town halls. We’re equally passionate about our team and ensuring each member reaches their potential. We brave new challenges together. That’s how we find better ways to get things done and break down barriers. It’s also how we make it fun to work here.
At Intercept, we foster an environment that celebrates creativity, collaboration, and mutual respect. We never hesitate to lean on our teammates and work together. Our relatively small size means you partner with accessible leaders who know you by name. This brings accountability and growth, which all add up to more opportunities to learn something new every day. A strong commitment to diversity, equity and inclusion is engrained in both our culture and our business. For self-motivated leaders who are ready to make a difference in the lives of patients, Intercept is a great place to be.
POSITION SUMMARY:
As Intercept continues to build its position as the leader in progressive non-viral liver disease, we are seeking an Associate Director, Clinical Contracts and Outsourcing. This position will be responsible for developing, implementing and managing new processes and systems to support R&D’s goal to make vendor contract and, change orders negotiations, and invoice review and approval tasks more efficient for the organization; and increasing the level of financial transparency and accountability within the R&D organization via implementation of effective contract management tactics and increased level of communications and information sharing with R&D contract owners.
CORE ACCOUNTABILITIES:
The successful candidate must be able to perform each of the following satisfactorily, with or without an accommodation:
QUALIFICATIONS:
REQUIRED KNOWLEDGE AND ABILITIES:
#LI-JJ1
#LI-Remote
From: Intercept Pharmaceuticals
Full Time
$140k-174k (estimate)
04/23/2023
05/19/2024
interceptpharma.com
New York, NY
1,000 - 3,000